InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
1
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-36.1%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Kong Garheng, Director. Officer active across 6 companies, notably Strongbridge Biopharma plc. Cumulatively, 17 reports have been logged. Breakdown: 1 buy · 0 sell. Activity tracked since 14 May 2021. The latest transaction was disclosed on 4 June 2025 (Attribution). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Kong Garheng
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations17 total
897 sharesCommon StockSEC:0000920148-26-000074:0
50,000 shares0Common StockSEC:0001867096-25-000106:0
944 sharesCommon StockSEC:0001127602-25-003707:0
50,000 shares0Common StockSEC:0001867096-24-000104:0
6,474 sharesCommon StockSEC:0001867096-24-000041:0
947 sharesCommon StockSEC:0001127602-24-003889:0
42,500 shares0Common StockSEC:0001867096-23-000101:0
742 sharesCommon StockSEC:0001127602-23-005110:0
15,000 shares0Common StockSEC:0001867096-22-000097:0
771 sharesCommon StockSEC:0001127602-22-003269:0
1,600,000 shares@ €1.1150.0% of flowCommon SharesSEC:0001567619-21-022249:0
Canonical exit: 15 Mar 2022 (T+90)
50,170 sharesCommon StockSEC:0000899243-21-039750:0
63,993 sharesOrdinary SharesSEC:0001179110-21-009278:0
50,170 sharesCommon StockSEC:0000899243-21-039342:0
17,763 shares@ US$2.0645.8% of flowOrdinary SharesSEC:0001179110-21-009219:0
40,000 shares0Ordinary SharesSEC:0001179110-21-005556:0
19,200 shares@ US$2.3554.2% of flowOrdinary SharesSEC:0001179110-21-005450:0
17 of 17 declarations
About Kong Garheng
Kong Garheng is Administrateur. He has 17 filings in total, and across the 17 recent sampled filings, the buy and sell amounts are EUR 0, with filings ranging from 2021-05-17 to 2026-02-13. His filings concern Strongbridge Biopharma plc, Xeris Biopharma Holdings, Inc. and LABCORP HOLDINGS INC., among the listed companies.
